Prospective Multi-center Study Using a Bronchoscopic Ultrasound-Guided Needle Biopsy System With Real-time Visualization in Endobronchial Lesions, Peripheral Lung Nodules, or Lung Masses

The purpose of this study is to collect information on the iNod™ System's safety and ability to see the iNod™ biopsy needle in real-time in endobronchial lesions, peripheral lung nodules, or lung masses.

Start Date01 Jan 2025

Sponsor / Collaborator

Boston Scientific Corp.

NCT06597968 / Not yet recruitingNot ApplicableIIT

Performance Estimation of Triaging Artificial Intelligence Based Computer-Aided Detection Algorithm in Routine Chest Radiography

chest x-rays will be analyzed by AI software for a secondary read of lung nodules. Chest x-rays will either be sent to the AI tool to be read or to radiologists to read. If the image is sent to the AI tool, the AI software will generate a report on if it detects a lung nodule or not. The image will then be sent to a radiologist to determine if there is agreement or disagreement with the AI tool.

Start Date01 Nov 2024

Sponsor / Collaborator

University Hospitals Cleveland Medical Center

ChiCTR2400090681 / RecruitingEarly Phase 1IIT

Research on the integration of Precision medicine detection and diagnosis and treatment of lung cancer

Start Date11 Oct 2024

Sponsor / Collaborator

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

100 Clinical Results associated with Nodule of lung

100 Translational Medicine associated with Nodule of lung

0 Patents (Medical) associated with Nodule of lung

437

Literatures (Medical) associated with Nodule of lung

01 Dec 2024·Preventive Medicine

“I've been really happy since I got that letter!”: Longitudinal patient perspectives on lung cancer screening communication

Article

Author: Ono, Sarah ; Davis, James ; Melzer, Anne C ; Golden, Sara E ; Golden, Sara E. ; Melzer, Anne C. ; Datta, Santanu ; Schweiger, Liana ; Slatore, Christopher

OBJECTIVEExperts recommend structured shared decision making when discussing lung cancer screening (LCS) and reporting low-dose computed tomography (LDCT) results. We examined patients' reactions to pre- and post-LDCT results communication processes at three medical centers in the US with established LCS programs.METHODSMulticenter, qualitative, longitudinal study of patients considering and receiving LCS using data from semi-structured interviews guided by a patient-centered communication model using conventional content analysis. We conducted 61 interviews among 32 patients (sixteen of whom had a nodule on their LDCT) at one month and 12 months after an initial LCS decision making interaction.RESULTSParticipants were mostly satisfied with LCS communication processes pre- and post-LDCT even though guideline concordant shared decision making was rare. Most participants reported no more than mild distress even if the LDCT detected a pulmonary nodule, felt relief after getting the results, and reported the perceived benefits of LCS outweighed their distress. Nearly all participants were satisfied with recommended follow-up plans. They reported that they trusted their clinicians and health care system to provide appropriate care and recommendations. They did not appear to regret their decision since almost all participants planned to get their next LDCT. However, they were at risk of non-adherence to follow-up recommendations since they often relied on the health care system to ensure they received timely follow-up.CONCLUSIONSDespite receiving guideline discordant decision-making communication, patients seem very satisfied, rarely experience severe distress, and have low decisional regret after LCS decision making and receiving the results of their LDCT.

01 Dec 2024·Computerized Medical Imaging and Graphics

An anthropomorphic diagnosis system of pulmonary nodules using weak annotation-based deep learning

Article

Author: Mao, Wenjun ; Sun, Min ; Archer, Michael A. ; Tong, Yubing ; Xu, Yongrui ; Archer, Michael A ; Xie, Lipeng ; Chen, Yundi ; Wan, Yuan ; Zheng, Mingfeng

The accurate categorization of lung nodules in CT scans is an essential aspect in the prompt detection and diagnosis of lung cancer. The categorization of grade and texture for nodules is particularly significant since it can aid radiologists and clinicians to make better-informed decisions concerning the management of nodules. However, currently existing nodule classification techniques have a singular function of nodule classification and rely on an extensive amount of high-quality annotation data, which does not meet the requirements of clinical practice. To address this issue, we develop an anthropomorphic diagnosis system of pulmonary nodules (PN) based on deep learning (DL) that is trained by weak annotation data and has comparable performance to full-annotation based diagnosis systems. The proposed system uses DL models to classify PNs (benign vs. malignant) with weak annotations, which eliminates the need for time-consuming and labor-intensive manual annotations of PNs. Moreover, the PN classification networks, augmented with handcrafted shape features acquired through the ball-scale transform technique, demonstrate capability to differentiate PNs with diverse labels, including pure ground-glass opacities, part-solid nodules, and solid nodules. Through 5-fold cross-validation on two datasets, the system achieved the following results: (1) an Area Under Curve (AUC) of 0.938 for PN localization and an AUC of 0.912 for PN differential diagnosis on the LIDC-IDRI dataset of 814 testing cases, (2) an AUC of 0.943 for PN localization and an AUC of 0.815 for PN differential diagnosis on the in-house dataset of 822 testing cases. In summary, our system demonstrates eﬀicient localization and differential diagnosis of PNs in a resource limited environment, and thus could be translated into clinical use in the future.

01 Dec 2024·European Journal of Radiology

Is there value in the routine inclusion of chest computed tomography for patients with gastrointestinal stromal tumor?

Article

Author: Chan, Wen-Hui ; Shen, Min-Ru ; Lai, Ying-Chieh ; Chen, Chien-Ming

PURPOSENational Comprehensive Cancer Network guidelines suggest chest CT when gastrointestinal stromal tumors are larger than 2 cm. We evaluate the value of screening the chest region during initial and follow-up CT.METHODSingle institution retrospective analysis of GIST cancer registry for patients diagnosed between May 2010 and November 2019 with tumor > 2 cm. We collected the patient demographics and clinical data; reviewed all CT scans of the chest region and recorded the lung nodules. Patients were grouped into lung nodule group and non-nodule group. Categorical variables were compared with the Chi square test and continuous variables with the Mann-Whitney U test. The survival probability was determined from Kaplan-Meier survival analysis and log-rank test for comparing differences.RESULTSThe final cohort included 382 patients (median age 61 years-old [interquartile range: 52-71]) and grouped into non-nodule group (n = 284) and lung nodule group (n = 98). The frequency of the CT scan was more in lung nodule group (8 [5-12]) than in non-nodule group (4 [2-9], p < 0.001). The lung nodule group had more CT including the chest region (6 [3-10] vs 3 [1-7], p < 0.001). In progressive lung nodules (8/98 [8 %]), only one patient had confirmed lung metastasis from GIST (1/382 [3 %]). There was no difference in overall survival between nodule groups (p = 0.12).CONCLUSIONSGIST patients with tumors larger than 2 cm have extremely low risk for lung metastasis. Routine inclusion of chest CT scan in staging and follow up is unnecessary.

News (Medical) associated with Nodule of lung

29 Oct 2024

·www.globenewswire.com

Biodesix to Participate in Three Investor Conferences in November

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences: Craig-Hallum 15th Annual Alpha Select Conference1x1 MeetingsDate: Tuesday, November 19, 2024Location: New York, NY Wolfe Research Healthcare Conference 20241x1 MeetingsDate: Wednesday, November 20, 2024Location: New York, NY Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum Presentation and 1x1 MeetingsPresentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ETLocation: New York, NY The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com. About Biodesix Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com. Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc. Contacts: Media:Natalie St. DenisNatalie.StDenis@biodesix.com1-720-925-9285 Investors:Chris Brinzeychris.brinzey@westwicke.com1-339-970-2843

Diagnostic Reagents

18 Oct 2024

·www.mobihealthnews.com

Presagen sells IVF AI to Astec and more briefs

Presagen divests IVF AI line to Japanese manufacturer Adelaide-based Presagen has sold its line of AI solutions for in vitro fertilisation to Japanese assisted reproductive technology manufacturer, Astec. The Life Whisperer series assesses embryo and oocyte images. It features AI algorithms that determine an embryo's likelihood of leading to pregnancy and being genetically normal, evaluate its morphological quality, as well as predict if oocytes can form a good-quality embryo or blastocyst. "We believe AI will be a core feature of every IVF lab in the future and we are delighted to offer our customers one of the most advanced and validated products in the market," Astec deputy CEO Takeo Cho said about their acquisition of Life Whisperer, which it has already made available in Japan and Indonesia. Following this sale, Astec will proceed with a global rollout of the IVF AI solutions. Sorsix absorbs New Zealand partner Australian health IT company Sorsix has acquired Aceso Health, one of its partners in New Zealand. Aceso has been the main carrier of Sorsix's digital health solutions, including the comprehensive cloud-based hospital system platform Pinga, in New Zealand since 2018. This acquisition, according to Aceso, will allow Sorsix to focus on its work and engagements in New Zealand by taking over its related party contracts and business. Orion Health announces integration with Te Whatu Ora's Streamliners Orion Health has partnered with Streamliners, a company jointly owned by The Joined Up Systems Trust and Te Whatu Ora, for technology integration. They will offer a combined solution by integrating Orion's Amadeus digital care records and Streamliners' HealthPathways, an online clinicians' manual that provides access to the latest global evidence and best practice guidelines on various health conditions. Based on a media release, the integrated offering will "enhance care coordination, clinical decision-making, and population health management across multiple care settings." Integral Diagnostics trials new chest CT AI ASX-listed medical imaging service provider Integral Diagnostics is trialling new chest CT-based AI algorithms ahead of its participation in the Australian government's National Lung Cancer Screening Programme (NLCSP) next year. According to a media release, it has extended its existing partnership deal with Israeli company Aidoc, which provides the aIOS platform that it has been using to flag critical chest and brain pathologies since 2019. The new AI on aIOS reportedly measures and alerts radiologists of lung nodules in chest CT scans. The NLCSP will begin screening people at high risk of lung cancer in July next year.

Acquisition

08 Oct 2024

·www.prnewswire.com

Baird Medical to Participate in Roth's 3rd Annual Healthcare Opportunities Conference

GUANGZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances, today announced that the Company will participate in the following investor conference. Baird Medical's management plans to host one-on-one and small group meetings with institutional investors at the conference. Roth's 3rd Annual Healthcare Opportunities Conference Wednesday, October 9, 2024 Metropolitan Club, 1 E 60th Street, New York, NY, 10022 Baird Medical's participation in the event comes as the Company expands its footprint in the U.S. market following recent FDA clearance for its minimally invasive microwave ablation technology, which offers a promising alternative to thyroidectomy for patients with benign thyroid tumors. Currently, 150,000 thyroidectomies are performed in the U.S. annually. About Baird Medical Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading microwave ablation ("MWA") medical device manufacturer and provider in China and a recent entrant to the United States market. Baird Medical's proprietary medical devices are used for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung nodules and breast lumps. Baird Medical is the first company to obtain a Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For more information, please visit . Contacts Investor Relations Robin Yang, Partner ICR, LLC Phone: +1 (646) 308-1475 Email: [email protected] Public Relations Brad Burgess, Senior Vice President ICR, LLC Phone: +1 (646) 588-0383 Email: [email protected] SOURCE Baird Medical Investment Holdings Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nodule of lung

Basic Info

Related

Analysis